Skip to Main content Skip to Navigation
Journal articles

A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients

Abstract : This was a phase I/II study testing the feasibility of a vaccine by autologous leukemic apoptotic corpse-pulsed dendritic cells (DC) in elderly acute myeloid leukemia (AML) patients in first or second complete remission. Pulsed DC were administered at doses of 9 × 106 subcutaneously (1 mL) and 1 × 106 intra-dermally (0.1 mL). Five doses of vaccine were planned on days +1 + 7 + 14 + 21 and +35. Five DC-vaccines were produced and injected for all five patients included in the study. No severe adverse event was documented. Larger Phase 2 studies are now required to precise the role of DC-vaccines with leukemic apoptotic bodies in older as well as younger AML populations.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03335625
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Monday, September 6, 2021 - 1:33:31 PM
Last modification on : Wednesday, October 20, 2021 - 3:19:34 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

`

Citation

Patrice Chevallier, Soraya Saiagh, Virginie Dehame, Thierry Guillaume, Pierre Peterlin, et al.. A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Human Vaccines & Immunotherapeutics, Taylor & Francis, 2021, Online ahead of print. ⟨10.1080/21645515.2021.1943991⟩. ⟨inserm-03335625⟩

Share

Metrics

Record views

15